MJ stocks 2019 — the best MJ stocks of 2019 — make one of the best investments this year. The hottest sector in the US as of March 1 has been MSO dispensaries. “Seed to Sale” outfits like Cresco Labs, Trulieve and Curaleaf. And these three, by the way, are among the very few of more than 300 cannabis stocks that have reported a profit as well as surging revenue growth.
US Hemp Stocks
Charlotte’s Web has been the best performer in this up and coming sector of the cannabis industry. And Cresco Labs just launched hemp-based CBD products and plans to sell them in all 50 states. Others to watch for are SOL Global and Veritas Farms.
Latin American Cannabis Stocks
Another of the top MJ stocks 2019 is Khiron. Also a seed to sale outfit, this Colombian-based company’s stock has triple since I bought in. And analysts project it will continue to rise in value. Because Khiron also operates in Chile, Peru, Argentina, and Mexico.
And their Kuida line of cosmeceuciticals will soon be on the shelves in the US, too. Plus their deal with Dixie Brands will give them 100+ cannabis-infused products to sell in Latin America.
This makes Dixie a potential big winner in 2019.) And Dixie products will move into Michigan in March, 2019, and edibles are legal there. Also moving into Canada with a done deal after October, 2019.
Other LATAM marijuana stocks to keep an eye on are Blueberries Medical, Pharmacielo and Organto Foods.
Hexo, Cronos and Organigram have out shined even the big caps that earn most revenue in Canada. Also, Aphria, Canntrust, Canopy Growth and Tilray have also done well in the big cap arena.
Note that today, investment bank Jefferies issued a sell recommendation for Hexo and Cronos. They projected a 24% downside.
Next Top MJ Stocks 2019
These are some of the best performing cannabis stocks of 2019 so far. For updates on the next ones, see my blog and sign up for free email updates of my posts. Find more cannabis stocks news at MarijuanaStox.com.
Disclosure: I am long on Trulieve, Cresco Labs, Dixie Brands, Charlotte’s Web, Khiron, Pharmacielo and Organto. Why wouldn’t I be? After all, I do follow my own advice.
Disclaimer: All material in this blog and its pages is provided for informational purposes only and does not constitute financial advice. The administrator, members and posters do not accept liability for your use of the posts, comments or content of this blog, which is provided on an “as is” and “as available” basis, without any representations, warranties or conditions of any kind.